Ocular drug delivery system advancement


Published on

Find more related content at www.PharmInfopedia.com

Ocular drug delivery system advancement

  2. 2. 2 CONTENTSObjectivesIntroductionAnatomy Of EyeBarriers In Ocular AbsorptionOcular AbsorptionUse of Mucoadhesives in Ocular Drug DeliveryNanoparticulate Dug DeliveryOcular InsertsLiposomes In Ocular Drug DeliveryFuture trendsConclusionReferences
  3. 3. 3 OBJECTIVESTo study the ocular drug delivery system in detail.To explore the success, limitations and future trends of ocular drug delivery system.
  4. 4. 4 INTRODUCTION• A drug delivery to circumvent ailments of eye.• A challenge to formulator is to avoid protective barrier of eye• Importance of cornea.• Conventional ocular drug delivery system• Need of a successful design
  5. 5. 5
  8. 8. 8 BARRIERS IN OCULAR ABSORPTIONPrecorneal Constraints Corneal constraintsIt include –• Solution drainage • Cornea as rate limiting barrier• Lacrimation • Anatomy of cornea• Tear dilution 1.Outer-Epithelium(lipophilic),• Tear turnover 2.Middle-Stroma(hydrophilic),• Conjunctival absorption 3.Inner-Endothelium(lipophilic
  12. 12. 12USE OF MUCOADHESIVES IN OCULAR DRUG DELIVERY• Mucoadhesives contain the dosage form which remains adhered to cornea until the polymer is degraded or mucus replaces itself.• Types-1. Naturally Occurring Mucoadhesives- Lectins, Fibronectins2. Synthetic Mucoadhesives-PVA,Carbopol, carboxy methyl cellulose, cross-linked polyacrylic acid• Drugs incarporated in to this are pilocarpine, lidocaine, benzocaine and prednisolone acetate.
  13. 13. 13Mechanism of mucoadhesion • The polymer undergoes swelling in water, • Entanglement of the polymer chains with mucin on the epithelial surface. • The un-ionized carboxylic acid residues on the polymer form hydrogen bonds with the mucin. • The water-swellable yet water- insoluble systems are preferred
  15. 15. 15Advantages of nanoparticles• Sustained drug release and prolonged therapeutic activity• Site-specific targeting• Higher cellular permeability• Protect the drug from chemical or enzymatic hydrolysis• Efficient in crossing membrane barriers -blood retinal barrier• Act as an inert carrier for ophthalmic drugs
  16. 16. 16Preparation of Nanoparticles Solvent evaporation method
  17. 17. 17
  18. 18. 18 OCULAR INSERTS• Sterile preparations, with a thin, multilayered, drug- impregnated, solid or semisolid consistency devices placed into cul-de-sac or conjunctival sac.Advantages• Increasing contact time and thus improving bioavailability.• Providing a prolong drug release and thus a better efficacy.• Reduction of systemic side effects and thus reduced adverse effects.• Reduction of the number of administrations and thus better patient compliance.
  19. 19. 19 Desired criteria for ocular inserts* Ease of handling and insertion* Lack of expulsion during wear* Reproducibility of release kinetics (Zero-order drug delivery)* Applicability to variety of drugs* Non-interference with vision and oxygen permeability.* Sterility.* Ease of manufacture
  20. 20. 20
  21. 21. 21A) Insoluble inserts- 1. Diffusional Inserts : •Central reservoir of drug enclosed in Semi permeable or microporous membrane for diffusion of drug. •Diffusion is controlled by Lacrimal Fluid penetrating through it. •Release follows : Zero Order Kinetics.e.g. Ocusert®: 20-40µg/hr for 7day Annular ring : Impregnated with Ti02 : For Visibility
  22. 22. 22 2) Osmotic inserts • A central part surrounded by a peripheral part • Central part-single reservoir or two distinct compartments. • Peripheral part- an insoluble semi permeable polymer. •The tear fluid diffuse and induces dissolution. •Solubilized deposits generate a hydrostatic pressure. •Drug is then released through these apertures3) Contact Lens :• Presoaked Hydrophilic lens.• Drug Release : within 1st 30 Min.• Alternate approach : incorporate drug either as soln or suspension .e.g. Pilocarpine.• Release rate is up to : 180 hr.
  23. 23. 23B) Soluble Inserts 1.SODI: Soluble Ocular Drug Insert. • Small water soluble made of soluble synthetic polymers. • Composition : Acryl amide, Vinyl Pyrolidone, Ethylacrylate. • Weight 15-16 mg. In 10-15 sec Softens; In 10-15 min. turns in Viscous Liquids; After 30-60min. Becomes Polymeric Solution. Advantages of SODI : •Single SODI application : replaces 4-12 eye drops Instillation, or 3-6 application of Ointments. •Once a day treatment of Glaucoma.
  24. 24. 242.The corneal collagen shield• A disposable, short-term therapeutic bandage lens for the cornea.• It conforms to the shape of the eye, protects the corneal surface, and provides lubrication as it dissolves.• The shields are derived from bovine collagen and are 14.5 mm in diameter.• Sterilized by gamma irradiation.Disadvantages1.It is not optically clear.2.The collagen shield causes some discomfort.Clinical uses1.Wound healing.2.Treatment of dry eye.
  25. 25. 25C) Biodegradable inserts 1.Lacrisert: • Sterile, Rod Shaped device. • Composition: HPC. • Weight:5mg, • Dimension:Diameter:12.5mm, Length:3.5mm • Use:-Dry eye treatment. 2.Minidisc: • It is made up of counter disc with Convex front & Concave back surface in contact with eye ball. • 4-5mm in diameter. • Composition : Silicon based polymer. • Drug release upto170 hr.
  26. 26. 26LIPOSOMES
  27. 27. 27
  28. 28. 28Preparation Of LiposomesReverse phase evaporation method
  29. 29. 29 Degradation and Drug Release Of Liposomes1. Endocytosis 2. Fusion
  30. 30. 30 FUTURE TRENDSThe sustained and controlled release technologies are being proposed and the possible benefits of using liposomes, nanoparticles and inserts will be at store in future.Targeted drug delivery with modifications of conventional, advanced and novel ocular drug deliveries has potential as future drug delivery for eye.It is possible to the give effective ocular drug delivery to any part of the eye.
  31. 31. 31 CONCLUSION• Very few advanced ocular drug delivery systems have been commercialized.• The performance of these new products, however, is still far from being perfect.• Major improvements are required in each of the technologies discussed in this study.• More clinical studies are necessary to provide further information and insights into these advanced ocular drug delivery systems.
  32. 32. 32 REFERENCES• Mitra Ashim k., Opthalmic Drug Delivery System, Marcel Dekker Inc., 1993,1-59,83-111,199-289.• Jain N.K., Controlled and Novel Drug Delivery, CBS Publisher, 2004, 82-100.• Das Swarnali, K. Preeti, Drug delivery to eye: Special reference to nanoparticles, International Journal of Drug Delivery 2, 2010, 12-21.• Rathore K. S., R. Nema, Review on Ocular Inserts Int.J. PharmTech Res.2009, 1(2),164-169.Web Searched:• http://www.google/images/eye/anatomy& physiology
  33. 33. 33The eyes are the mirror of the soul… Take care of your eyes with gentleness.